Pharmaceuticals (Jan 2022)

First In Silico Screening of Insect Molecules for Identification of Novel Anti-Parasitic Compounds

  • Tom L. Gallinger,
  • Samuel Y. Aboagye,
  • Wiebke Obermann,
  • Michael Weiss,
  • Arnold Grünweller,
  • Carlo Unverzagt,
  • David L. Williams,
  • Martin Schlitzer,
  • Simone Haeberlein

DOI
https://doi.org/10.3390/ph15020119
Journal volume & issue
Vol. 15, no. 2
p. 119

Abstract

Read online

Schistosomiasis is a neglected tropical disease caused by blood flukes of the genus Schistosoma. In silico screenings of compounds for the identification of novel anti-parasitic drug candidates have received considerable attention in recent years, including the screening of natural compounds. For the first time, we investigated molecules from insects, a rather neglected source in drug discovery, in an in silico screening approach to find novel antischistosomal compounds. Based on the Dictionary of Natural Products (DNP), we created a library of 1327 insect compounds suitable for molecular docking. A structure-based virtual screening against the crystal structure of a known druggable target in Schistosoma mansoni, the thioredoxin glutathione reductase (SmTGR), was performed. The top ten compounds predominantly originated from beetles and were predicted to interact particularly with amino acids in the doorstop pocket of SmTGR. For one compound from a jewel beetle, buprestin H, we tested and confirmed antischistosomal activity against adult and juvenile parasites in vitro. At concentrations with anti-parasitic activity, we could also exclude any unspecific cytotoxic activity against human HepG2 cells. This study highlights the potential of insect molecules for the identification of novel antischistosomal compounds. Our library of insect-derived molecules could serve not only as basis for future in silico screenings against additional target proteins of schistosomes, but also of other parasites.

Keywords